ERBB2 and ovarian neoplasm: In addition, preclinical studies of PET molecular probes labeled to HER2 affibody by radionuclides such as astatine-211 (211At), scandium-44 (44Sc), zirconium-89 (89Zr), and carbon-11 (11C) through different chelating agents in SKOV3 ovarian tumors with high HER2 expression have also been reported in the literature, and the results show good potential for clinical application (103–106).